GlassScriptPhysician profile
Steve M Aydin
NPI 1104099910
$21,917.90
in general payments reported to CMS, 2019-2025
47 companies · $415 in 2025
The $415 reported for 2025 was less than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,354 · 2020: $3,338 · 2021: $2,701 · 2022: $5,602 · 2023: $6,748 · 2024: $1,759 · 2025: $415.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,500 · Food and Beverage: $1,967 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $857 · Travel and Lodging: $598.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,500.00 |
| Food and Beverage | $1,966.89 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $857.00 |
| Travel and Lodging | $598.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertos Medical, INC. | $13,251.55 | 2020-2024 | Mild Device Kit |
| Pfizer INC. | $2,736.77 | 2019-2021 | |
| Stryker Corporation | $946.67 | 2019-2025 | Mako, Omnicurve, Pangea |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $857.00 | 2023 | Relistor |
| Depuy Synthes Sales INC. | $468.80 | 2019-2022 | |
| Amgen INC. | $373.29 | 2019-2024 | Evenity, Prolia |
| Relievant Medsystems, INC. | $368.44 | 2022 | |
| Vertiflex, INC. | $365.16 | 2019 | |
| Horizon Therapeutics Plc | $349.26 | 2019-2022 | |
| Ucb, INC. | $242.33 | 2021-2025 | Cimzia, Bimzelx |
| Abbott Laboratories | $192.99 | 2020-2024 | Eterna |
| Zyla Life Sciences, INC. | $141.94 | 2019-2020 | |
| Boston Scientific Corporation | $140.66 | 2019-2021 | |
| Ibsa Pharma INC. | $131.80 | 2021-2025 | Licart, Tirosint, Flector |
| Si-Bone, INC. | $125.54 | 2019-2021 |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steve Aydin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.